Regulation of T cell activation in vitro and in vivo by targeting the OX40-OX40 ligand interaction: amelioration of ongoing inflammatory bowel disease with an OX40-IgG fusion protein, but not with an OX40 ligand-IgG fusion protein - PubMed (original) (raw)

. 1999 Jan 1;162(1):486-93.

Affiliations

PMID: 9886424

Regulation of T cell activation in vitro and in vivo by targeting the OX40-OX40 ligand interaction: amelioration of ongoing inflammatory bowel disease with an OX40-IgG fusion protein, but not with an OX40 ligand-IgG fusion protein

L M Higgins et al. J Immunol. 1999.

Abstract

OX40 is a member of the TNFR superfamily, and is found predominantly on activated CD4-positive T cells. In vitro an OX40-IgG fusion protein inhibits mitogen- and Ag-driven proliferation and cytokine release by splenocytes and lymph node T cells. In contrast, an OX40 ligand-IgG fusion protein enhanced proliferative responses. In normal mice, OX40-positive cells are observed only in lymphoid tissues, including Peyer's patches of the gut. In mice with hapten-induced colitis or IL-2 knockout mice with spontaneous colitis, OX40-positive cells are found infiltrating the lamina propria. Administration of the OX40-IgG fusion protein to mice with ongoing colitis (but not the OX40 ligand-IgG) ameliorated disease in both mouse models of inflammatory bowel disease. This was evidenced by a reduction in tissue myeloperoxidase; reduced transcripts for TNF-alpha, IL-1, IL-12, and IFN-gamma; and a reduction in the T cell infiltrate. Targeting OX40 therefore shows considerable promise as a new strategy to inhibit ongoing T cell reactions in the gut.

PubMed Disclaimer

Cited by

Compromised OX40 function in CD28-deficient mice is linked with failure to develop CXC chemokine receptor 5-positive CD4 cells and germinal centers.
Walker LS, Gulbranson-Judge A, Flynn S, Brocker T, Raykundalia C, Goodall M, Förster R, Lipp M, Lane P. Walker LS, et al. J Exp Med. 1999 Oct 18;190(8):1115-22. doi: 10.1084/jem.190.8.1115. J Exp Med. 1999. PMID: 10523609 Free PMC article.
Pimecrolimus inhibits up-regulation of OX40 and synthesis of inflammatory cytokines upon secondary T cell activation by allogeneic dendritic cells.
Kalthoff FS, Chung J, Stuetz A. Kalthoff FS, et al. Clin Exp Immunol. 2002 Oct;130(1):85-92. doi: 10.1046/j.1365-2249.2002.01962.x. Clin Exp Immunol. 2002. PMID: 12296857 Free PMC article.
Expression of OX40 (CD134) on CD4+ T-cells from patients with myasthenia gravis.
Xiaoyan Z, Pirskanen R, Malmstrom V, Lefvert AK. Xiaoyan Z, et al. Clin Exp Immunol. 2006 Jan;143(1):110-6. doi: 10.1111/j.1365-2249.2005.02955.x. Clin Exp Immunol. 2006. PMID: 16367941 Free PMC article.
Activation and Costimulation of Intestinal T Cells: Independent and Collaborative Involvement of CD43, OX40, and Ly-6C.
Montufar-Solis D, Klein JR. Montufar-Solis D, et al. Curr Immunol Rev. 2005 Jan;1(1):13-20. doi: 10.2174/1573395052952914. Curr Immunol Rev. 2005. PMID: 19081760 Free PMC article.
T cell accumulation in B cell follicles is regulated by dendritic cells and is independent of B cell activation.
Fillatreau S, Gray D. Fillatreau S, et al. J Exp Med. 2003 Jan 20;197(2):195-206. doi: 10.1084/jem.20021750. J Exp Med. 2003. PMID: 12538659 Free PMC article.

Regulation of T cell activation in vitro and in vivo by targeting the OX40-OX40 ligand interaction: amelioration of ongoing inflammatory bowel disease with an OX40-IgG fusion protein, but not with an OX40 ligand-IgG fusion protein - PubMed (original) (raw)